Status:
SUSPENDED
Detecting HPV DNA in Anal and Cervical Cancers
Lead Sponsor:
University of Chicago
Conditions:
Cervical Cancer
Anal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this...
Eligibility Criteria
Inclusion
- Stage I-III anal cancer or stage I-IVA cervical cancer that is p16+ based on immunohistochemistry.
- Age ≥ 18 years
- Planned to undergo radiation therapy as definitive treatment, with or without concurrent systemic therapy
Exclusion
- Anal carcinoma not associated with HPV-16, 18, 31, 33, or 35 will be removed from the
- Planned to undergo radiation therapy as an adjuvant or post-operative therapy
Key Trial Info
Start Date :
October 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 15 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04857528
Start Date
October 6 2020
End Date
November 15 2027
Last Update
June 8 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
2
University of Chicago
Chicago, Illinois, United States, 60637